Remdesivir in adults with severe COVID-19 : a randomised, double-blind, placebo-controlled, multicentre trial

Wang, Y. and Zhang, D. and Du, G. and Du, R. and Zhao, J. and Jin, Y. and Fu, S. and Gao, L. and Cheng, Z. and Lu, Q. and Hu, Y. and Luo, G. and Wang, K. and Lu, Y. and Li, H. and Wang, S. and Ruan, S. and Yang, C. and Mei, C. and Ding, D. and Wu, F. and Tang, X. and Ye, X. and Ye, Y. and Liu, B. and Yang, J. and Yin, W. and Wang, A. and Fan, G. and Zhou, F. and Liu, Z. and Gu, X. and Xu, J. and Shang, L. and Zhang, Y. and Cao, L. and Guo, T. and Wan, Y. and Qin, H. and Jiang, Y. and Jaki, T. and Hayden, F.G. and Horby, P.W. and Cao, B. and Wang, C. (2020) Remdesivir in adults with severe COVID-19 : a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. pp. 1569-1578. ISSN 0140-6736

Text (THELANCET-S-20-09798 (2))
THELANCET_S_20_09798_2_.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.
Download (1MB)

Abstract

Summary Background No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside analogue prodrug, has inhibitory effects on pathogenic animal and human coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro, and inhibits Middle East respiratory syndrome coronavirus, SARS-CoV-1, and SARS-CoV-2 replication in animal models. Methods We did a randomised, double-blind, placebo-controlled, multicentre trial at ten hospitals in Hubei, China. Eligible patients were adults (aged ≥18 years) admitted to hospital with laboratory-confirmed SARS-CoV-2 infection, with an interval from symptom onset to enrolment of 12 days or less, oxygen saturation of 94% or less on room air or a ratio of arterial oxygen partial pressure to fractional inspired oxygen of 300 mm Hg or less, and radiologically confirmed pneumonia. Patients were randomly assigned in a 2:1 ratio to intravenous remdesivir (200 mg on day 1 followed by 100 mg on days 2–10 in single daily infusions) or the same volume of placebo infusions for 10 days. Patients were permitted concomitant use of lopinavir–ritonavir, interferons, and corticosteroids. The primary endpoint was time to clinical improvement up to day 28, defined as the time (in days) from randomisation to the point of a decline of two levels on a six-point ordinal scale of clinical status (from 1=discharged to 6=death) or discharged alive from hospital, whichever came first. Primary analysis was done in the intention-to-treat (ITT) population and safety analysis was done in all patients who started their assigned treatment. This trial is registered with ClinicalTrials.gov, NCT04257656. Findings Between Feb 6, 2020, and March 12, 2020, 237 patients were enrolled and randomly assigned to a treatment group (158 to remdesivir and 79 to placebo); one patient in the placebo group who withdrew after randomisation was not included in the ITT population. Remdesivir use was not associated with a difference in time to clinical improvement (hazard ratio 1·23 [95% CI 0·87–1·75]). Although not statistically significant, patients receiving remdesivir had a numerically faster time to clinical improvement than those receiving placebo among patients with symptom duration of 10 days or less (hazard ratio 1·52 [0·95–2·43]). Adverse events were reported in 102 (66%) of 155 remdesivir recipients versus 50 (64%) of 78 placebo recipients. Remdesivir was stopped early because of adverse events in 18 (12%) patients versus four (5%) patients who stopped placebo early. Interpretation In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits. However, the numerical reduction in time to clinical improvement in those treated earlier requires confirmation in larger studies.